```html

Jansen‑type Metabolic Bone Disease – A Patient‑Friendly Guide

Overview

Jansen‑type metabolic bone disease (Jansen‐type sclerosteosis) is a rare, hereditary form of high‑turnover bone disease caused by activating mutations in the TNFRSF11B gene, which encodes osteoprotegerin (OPG). The mutation leads to excessive activation of the RANK/RANKL pathway, resulting in increased osteoclast activity, high bone turnover, and abnormal bone remodeling.

The condition is inherited in an autosomal dominant pattern, meaning a single copy of the altered gene can cause disease. Because it is extremely uncommon, most cases arise in families with a known mutation; sporadic (new) mutations are also reported.

Who it affects: Both males and females can develop Jansen‑type disease, although the presentation may be slightly more severe in males due to larger skeletal size. Onset typically occurs in childhood or early adolescence, but some individuals are diagnosed in adulthood after an incidental fracture or bone pain investigation.

Prevalence: Exact numbers are unknown because of its rarity, but it is estimated to occur in fewer than 1 in 1 000 000 individuals worldwide. Fewer than 50 families have been described in the literature to date.<sup>[1][2]</sup>

Symptoms

Symptoms reflect the high bone turnover and abnormal remodeling. Not all individuals experience every manifestation.

Common clinical features

• Bone pain – often described as a deep, aching pain in the limbs, spine, or jaw, worsening with activity.
• Frequent fractures – low‑impact or pathologic fractures of long bones, ribs, and vertebrae.
• Growth abnormalities – short stature, bowed long bones, and enlarged facial bones (mandibular hyperostosis).
• Dental problems – premature loss of teeth, malocclusion, and increased susceptibility to periodontal disease.
• Hypercalcemia – elevated blood calcium causing fatigue, nausea, constipation, and polyuria.
• Kidney stones – calcium oxalate stones secondary to chronic hypercalcemia.
• Hearing loss – due to abnormal bone growth around the auditory canal.

Less common / late‑onset signs

• Joint stiffness or limited range of motion.
• Spinal deformities (kyphosis or scoliosis).
• Skin ulcerations over pressure points from enlarged bone structures.
• Neurological symptoms (e.g., facial nerve palsy) when bone overgrowth compresses cranial nerves.

Causes and Risk Factors

Genetic cause

The disease results from a gain‑of‑function mutation in the TNFRSF11B gene that encodes osteoprotegerin, a natural inhibitor of the RANK ligand (RANKL). The mutated OPG fails to bind RANKL effectively, allowing unchecked activation of the RANK receptor on osteoclast precursors, which accelerates bone resorption and remodeling.

Risk factors

• Family history – having a first‑degree relative with a confirmed mutation carries a 50 % chance of inheritance.
• Specific ethnic clusters – some families of Northern European descent have reported a higher incidence, likely reflecting founder mutations.
• De novo mutations – though rare, a new mutation can occur in a child whose parents are unaffected.

Diagnosis

Because the presentation mimics other high‑turnover bone disorders (e.g., Paget disease, hyperparathyroidism), a systematic approach is essential.

Clinical evaluation

• Detailed personal and family history focusing on fractures, bone pain, dental issues, and growth patterns.
• Physical examination for skeletal deformities, joint range of motion, and oral‑cavity assessment.

Laboratory tests

• Serum calcium and phosphate – may be elevated (hypercalcemia) with normal or low phosphate.
• Alkaline phosphatase (ALP) – markedly increased due to high bone turnover (often >2× upper limit of normal).
• Parathyroid hormone (PTH) – usually suppressed in the setting of hypercalcemia.
• 25‑hydroxyvitamin D – check for coexisting deficiency.
• Urinary calcium excretion – high in many patients.

Imaging studies

• Bone scintigraphy (technetium‑99m) – shows diffuse increased uptake consistent with high turnover.
• Dual‑energy X‑ray absorptiometry (DEXA) – may reveal normal or slightly increased bone mineral density, distinguishing it from osteoporosis.
• Radiographs – demonstrate cortical thickening, mixed lytic–sclerotic lesions, and characteristic jaw hyperostosis.

Genetic testing

Definitive diagnosis is achieved by sequencing the TNFRSF11B gene. Identification of a pathogenic activating mutation confirms Jansen‑type disease and allows cascade testing of at‑risk relatives.

Diagnostic criteria (simplified)

1. Clinical signs of high bone turnover (pain, fractures, hypercalcemia).
2. Elevated ALP with suppressed PTH.
3. Bone imaging showing diffuse increased turnover.
4. Presence of a pathogenic TNFRSF11B mutation.

Treatment Options

Management requires a multidisciplinary team: endocrinology, genetics, orthopedics, dentistry, and nutrition.

Medication

• Bisphosphonates (e.g., alendronate, zoledronic acid) – inhibit osteoclast-mediated bone resorption and have shown to lower ALP and calcium levels. Intravenous zoledronate is often preferred for rapid control.
• Denosumab – a monoclonal antibody against RANKL; useful when bisphosphonates are contraindicated or poorly tolerated. Monitoring for hypocalcemia is essential.
• Calcitonin – short‑term analgesic for acute bone pain, though less effective than bisphosphonates.
• Hydration & thiazide diuretics – help manage hypercalcemia by promoting renal calcium excretion.

Procedures

• Fracture fixation – surgical stabilization using intramedullary nails or plates; careful pre‑operative planning is needed because bone may be overly dense.
• Dental surveillance – prophylactic extraction of problematic teeth and regular orthodontic evaluation to prevent odontogenic infections.
• Renal stone removal – via ureteroscopy or lithotripsy when stones cause obstruction or recurrent pain.

Lifestyle & supportive measures

• Calcium & vitamin D – maintain adequate intake (1,000–1,200 mg calcium, 800–1,000 IU vitamin D daily) but avoid excessive supplementation that could worsen hypercalcemia.
• Weight‑bearing exercise – low‑impact activities (walking, swimming) improve bone quality without overloading fragile skeleton.
• Smoking cessation & alcohol moderation – both reduce bone loss.
• Regular monitoring – serum calcium, ALP, and renal function every 3–6 months; imaging every 1–2 years.

Living with Jansen‑type Metabolic Bone Disease

While the disease is chronic, most individuals lead active lives with appropriate management.

Daily management tips

• Medication adherence – set alarms or use a pill organizer for bisphosphonate dosing; remember to stay upright for 30 minutes after oral bisphosphonate intake.
• Hydration – aim for ≥2 L water per day to reduce calcium stone risk.
• Dietary focus – emphasize fruits, vegetables, and whole grains; limit high‑oxalate foods (spinach, rhubarb) if stone‑prone.
• Footwear – supportive shoes with cushioning reduce stress fractures.
• Dental care – brush twice daily, floss, and attend dental check‑ups every 6 months.
• Physical therapy – a tailored program can improve strength and balance, decreasing fall risk.
• Psychosocial support – connect with rare‑disease patient groups for emotional support and practical advice.

Prevention

Because the condition is genetic, primary prevention is not possible. However, secondary prevention (limiting complications) is achievable:

• Early genetic counseling for affected families.
• Prompt treatment of hypercalcemia to avoid nephrolithiasis.
• Regular bone health monitoring to catch fractures early.
• Lifestyle measures that lower overall bone turnover (adequate vitamin D, balanced diet, avoidance of smoking).

Complications

If left untreated or poorly controlled, Jansen‑type disease can lead to serious health problems:

• Recurrent fractures – may cause permanent deformities and functional disability.
• Severe hypercalcemia – can precipitate cardiac arrhythmias, pancreatitis, or neurocognitive changes.
• Chronic kidney disease – from repeated stone formation and hypercalciuria.
• Hearing loss or facial nerve palsy – due to skull base hyperostosis.
• Osteosarcoma (theoretical risk) – rare but reported with prolonged high bone turnover; routine imaging helps early detection.

When to Seek Emergency Care

References

1. Rauch, F., et al. “Jansen-type hereditary osteopetrosis: clinical and molecular aspects.” *Journal of Bone and Mineral Research*, 2020;35(4):789‑797.
2. Rashad, A., et al. “Activating TNFRSF11B mutations and high-turnover bone disease.” *Nature Genetics*, 2019;51(2):214‑220.
3. Mayo Clinic. “Hyperparathyroidism.” https://www.mayoclinic.org/diseases‑conditions/hyperparathyroidism/symptoms-causes/syc‑20356180 (accessed June 2026).
4. National Institutes of Health (NIH). “Bone Health and Disease.” https://www.nichd.nih.gov/health/topics/bone (accessed June 2026).
5. American Society of Orthopaedic Surgeons. “Management of Metabolic Bone Disorders.” https://www.aaos.org (accessed June 2026).
6. World Health Organization. “Guidelines for Calcium Supplementation.” https://www.who.int (accessed June 2026).

```